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Abstract 
Background: The clinical course of IgA nephropathy (IgAN) is variable and complement activation may predict 
prognosis. The present study investigated whether glomerular abundance of complement proteins associates with 
progression to end‑stage renal disease (ESRD) in patients for whom prognosis could not be predicted based on clini‑
cal variables.
Methods: Based on data from the Norwegian Kidney Biopsy Registry and the Norwegian Renal Registry, three 
groups were included: IgAN patients with (n = 9) or without (n = 16) progression to ESRD during 10 years, and 
controls (n = 15) with a normal kidney biopsy. IgAN patients had eGFR > 45 ml/min/1.73 m2 and non‑nephrotic pro‑
teinuria at time of biopsy. Using stored formalin‑fixed paraffin embedded kidney biopsy tissue, about 100 glomerular 
cross sections were microdissected for each patient. Samples were analyzed by liquid chromatography–tandem mass 
spectrometry and relative abundances of complement proteins were compared between groups.
Results: Proteomic analyses quantified 2018 proteins, of which 28 proteins belong to the complement system. As 
compared to IgAN patients without progressive disease, glomeruli from patients with progressive IgAN had signifi‑
cantly higher abundance of components of the classical and the terminal complement pathways, and inhibitory 
factors such as Factor H and factor H related proteins. Abundance of complement proteins classified progressors 
from non‑progressors with an area under ROC curve of 0.91 (p = 0.001). Clinical and morphological data were similar 
between the two patient groups and could not predict progressive IgAN.
Conclusions: In conclusion, higher glomerular abundance of complement proteins was associated with a progres‑
sive clinical course in IgAN and are candidate biomarkers to predict prognosis.
Keywords: IgA nephropathy, Complement, ESRD, Formalin‑fixed paraffin embedded kidney biopsy tissue,  
Liquid chromatography–tandem mass spectrometry, Proteomic analyses
© The Author(s) 2017. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Open Access
Clinical Proteomics
*Correspondence:  flavia.teodora.ioana.paunas@helse‑fonna.no;  
flavia_paunas@yahoo.com 
1 Department of Medicine, Haugesund Hospital, Postbox 2170, 
5504 Haugesund, Norway
Full list of author information is available at the end of the article
Page 2 of 12Paunas et al. Clin Proteom  (2017) 14:30 
Background
The clinical course of IgA nephropathy (IgAN) is highly 
variable and difficult to predict, some patients have a 
stable clinical course, while others progress to end-stage 
renal disease (ESRD). Several clinical and histological 
factors at time of diagnosis have been shown to indicate 
worse prognosis. These include low estimated glomerular 
filtration rate (eGFR), hypertension, proteinuria, mesan-
gial hypercellularity, segmental glomerulosclerosis or 
adhesion, tubular atrophy and interstitial fibrosis [1–3]. 
There is however a large group with moderate risk in 
which individual prognostication based on these factors 
is difficult and there is a clear need for better prognostic 
markers in this group [4].
It has long been suggested that complement has an 
important role in the pathogenesis of IgAN as comple-
ment components C3, properdin and factor H have been 
commonly co-detected with IgA deposits in renal biopsy 
specimens [5–7]. Complement activation can occur 
through the classical, lectin or alternative pathways [8–
11], that ultimately result in activation of the terminal 
complement pathway. Previous studies have shown that 
the lectin pathway [12, 13] and the alternative pathway 
[14] likely are involved in the pathophysiology of IgAN.
In the present study we investigated markers of pro-
gressive IgAN in patients with medium risk of progres-
sion based on eGFR and proteinuria. Patients were 
included in a case–control design comparing patients 
with progressive IgAN to non-progressive disease IgAN 
as well as to control patients. Glomerular cross sections 
were microdissected and glomerular protein abundances 
were compared between groups. Initial findings showed 
that complement related proteins seemed to be impor-
tant and we thus compared abundances of these proteins 
in progressive versus non-progressive IgAN andnon-
progressive IgAN versus healthy control patients and 
describe associations with clinical and morphological 
parameters. Lastly we investigate whether complement 
related proteins showed potential for prediction of pro-
gressive IgAN.
Methods
The study was approved by the Regional Committee for 
Medical and Health Research Ethics.
Registries used in the study
Data from the Norwegian Kidney Biopsy Registry were 
used for selection of patients. The registry has recorded 
clinical, biochemical and histopathological data at time 
of biopsy from nearly all patients who have undergone 
a non-neoplastic kidney biopsy in Norway since 1988. 
Serum creatinine, systolic blood pressure and urinary 
protein excretion at time of biopsy were used as reported 
to the registry. Creatinine was measured at the local hos-
pital laboratories using kinetic Jaffe method until about 
2005 when there was a swithch to the IDMS traceable 
enzymatic test, the switch was done at slightly different 
time points at different hospitals. In the present study, 
creatinine values measured before 2005 was recalculated 
based on a formula used by Hallan et  al. to recalibrate 
creatinine to IDMS-traceble values [15]. We calculated 
eGFR based on the the CKD-EPI equation [16]. Urinary 
protein was quantified as g/24  h either from directly 
measured values, by calculation from reported urinary 
protein to creatinine ratio or if only reported by urinary 
dipstick a negative dipstick was set to 0 g/24 h, 1+ was 
set to 0.5 g/24 h, 2+ was set to 1.0 g/24 h and 3+ was set 
to 3.0 g/24 h [4]. By using the 11-digit national identity 
number, data from the Norwegian Kidney Biopsy Regis-
try were linked with the Norwegian Renal Registry which 
has registed all cases with ESRD in Norway since 1980. 
At the time of linkage, data on ESRD were available until 
2013.
Study population
Based on data from the described registries, patients 
were selected for three subgroups. (1) Non-progres-
sive IgAN, criteria: diagnosis of IgAN at kidney biopsy, 
eGFR  >  45  ml/min/1.73  m2, urinary protein >1  g/24  h 
and no development of ESRD during a follow-up period 
of at least 10 years. (2) Progressive IgAN, criteria: diagno-
sis of IgAN at kidney biopsy, eGFR > 45 ml/min/1.73 m2, 
urinary protein <3.5  g/24  h and development of ESRD 
during the first 10  years after kidney biopsy. (3) Con-
trol patients, criteria: normal or minimal morphological 
changes in the kidney biopsy, eGFR > 60 ml/min/1.73 m2, 
urinary protein <0.5 g/24 h and no development of ESRD 
during a follow-up period of at least 10 years. All biopsies 
had been performed as part of a standard clinical work-
up where glomerular disease was suspected. By review 
of medical journals, data on steroid treatment were 
retrieved for all IgAN patients and last available serum 
creatinine and urinary protein were also retrieved for 
patients who had not developed ESRD.
Laser capture microdissection and sample preparation
The remaining part of the kidney biopsy core that was 
not used for diagnostic examination has been stored as 
formalin-fixed paraffin-embedded tissue and was used 
for the present study. Ten micrometer thick FFPE sec-
tions were deparaffinized, rehydrated and stained with 
haematoxylin–eosin. Glomeruli with global sclerosis, 
more than minimal segmental sclerosis, crescents or 
fibrinoid necrosis were excluded. Based on these crite-
ria, eligible glomeruli were laser microdissected (PALM 
MicroBeam, Zeiss) and pressure catapulted into a tube 
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cap (AdhesiveCap 500 clear, Zeiss). For each patient, 
we aimed to microdissect about 100 glomerular cross 
sections.
Microdissected FFPE glomeruli were suspended in 
10 µL lysis solution and stored at −20  °C until pep-
tide extraction. Protein extraction and trypsinization of 
microdissected glomeruli were performed as previously 
described [17].
Liquid chromatography and tandem mass spectrometry
The samples were analyzed on a Q-Exactive HF (Thermo 
Scientific) connected to a Dionex Ultimate NCR-3500RS 
LC system. The MS instrument was equipped with an 
EASY-spray ion source (Thermo Scientific) and MS spec-
tra were acquired as described in detail in the supple-
mental information documenting the detailed methods.
Label free quantification
The raw data was analyzed with the Progenesis LC–MS 
software (version 4.0, Nonlinear Dynamics, UK) using 
default settings.  Features were exported from Progen-
esis and imported into Proteome Discoverer (version 1.4, 
Thermo Scientific) for protein identification using the 
SwissProt human database (downloaded from UniProt 
August 2015, 20,197 sequences).
Histology and immunohistochemistry
The biopsies were reclassified in a blinded manner by an 
experienced nephropathologist (SL) using the Oxford 
classification scoring system and M, E, S and T scores 
were assigned [3]. Immunohistochemistry was per-
formed on 3  µm thick sections from FFPE tissue after 
antigen retrieval with proteinase digestion. The following 
antibodies were used: polycolonal rabbit anti-human C3c 
(Dako, Glostrup, Danmark; A0062), polyclonal rabbit-
antihuman C1q (Dako, Glostrup, Danmark; A0136) and 
monoclonal mouse anti-human C5b-9, clone aE11 (Dako, 
Glostrup, Danmark; M0777). The aE11 antibody detects 
a neoepitope exposed in C9 after C9 is incorporated in 
the C5b-9 complex and is not present in native C9, thus 
specifically deting activation of the whole complement 
cascade [18]. Nearly all biopsies had been stained for C3c 
and C1q at time of diagnostic evaluation and these sec-
tions were used for evaluation. For C5b-9 staining, new 
sections were used. Glomerular positivity for comple-
ment factors was evaluated by semiquantitative scoring 
ranging from 0 to 3+.
Statistics and bioinformatics
Clinical and morphological variables are described either 
as mean  ±  standard deviation or as percentages Tests 
of statistical significance were performed with t-tests or 
Chi-square statistics. Normalized protein abundances 
were compared between groups with t-tests and con-
sidered differently abundant if identified by at least two 
unique peptides and p value <0.05. Fold change is given 
for relative quantification of protein abundance between 
groups. Mean ± standard deviation is given where appro-
priate. Linear regression was performed to explore the 
relationship between complement proteins and clinical 
variables GFR, proteinuria and blood pressure.
A complement score was calculated for each IgAN 
patient by multiplying scores for all included complement 
proteins (score for each protein calculated as the protein 
abundance for the patient divided by mean protein abun-
dance for all patients with IgAN; for proteins with fold 
change <1 in the comparison between IgAN with progres-
sion divided with IgAN without progression, the score 
was exponentiated by −1). The complement score was 
logarithmically transformed. Receiving operating charac-
teristics (ROC) curves were used to evaluate the perfor-
mance of the complement protein score and area under 
the curve (AUC) were calculated. Two complement scores 
were calculated, one including all significant complement 
proteins and one including only proteins of the MAC 
complex (complement factors C5, C6, C7, C8 and C9). 
ROC curves were also created for systolic blood pressure, 
complement component C7 and 1/eGFR for comparison.
Results
Three groups were included and kidney biopsy tissue 
could be retrieved and enough glomeruli microdissected 
for 16 patients with non-progressive IgAN, 9 patients 
with progressive IgAN and 15 controls with normal biop-
sies. The clinical and morphological characteristics of 
the three groups are summarized in Table  1. There was 
no statistical significant difference in clinical charac-
teristics between IgAN patients with progressive versus 
non-progressive disease. Oxford classification showed no 
difference in M, E or S score between patients with versus 
without progression, T score was however more often 
positive in patients with progressive disease (44 vs 0%) 
(p = 0.004).
Glomerular proteome analysis
A total of 3274 proteins were identified, of which 2018 
were identified with two or more unique peptides and 
could thus be used in quantitative analyses. Of these, 231 
proteins had significant different abundance between 
progressive and non-progressive IgAN. The 25 most 
strongly significantly changed proteins in progressive 
versus non-progressive IgAN are listed in Table 2. Nota-
bly, 10 (40%) of these were complement proteins and we 
therefore chose to focus further studies towards comple-
ment proteins. In the list of all quantified proteins, 28 
were complement proteins.
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Table 1 Clinical characteristics and MEST classification of included patients at time of biopsy
* p < 0.05 as compared to control. No variables were statistically significant between IgAN with versus without progression
a Estimated by CKD-EPI equation
Controls IgAN without progression IgAN with progression
N 15 16 9
Year of diagnosis 2000 ± 7.7 1996 ± 3.4 1998 ± 5.7
Proportion female 53.3% 12.5% 33.3%
Age (years) 32.0 ± 11.9 31.4 ± 13.4 31.2 ± 15.8
Serum creatinine (μmol/l) 79.3 ± 20.9 91.5 ± 21.5 105.8 ± 25.6*
Estimated glomerular filtration  ratea (ml/min/1.73 m2) 113.13 ± 18.5 114.19 ± 25.3 91.89 ± 26.3*
Systolic blood pressure (mmHg) 118.6 ± 14.6 127.2 ± 14.3 135.4 ± 25.8
Diastolic blood pressure (mmHg) 77.6 ± 8.4 78.9 ± 11.6 78.8 ± 13.1
Urinary protein (g/24 h) 0.16 ± 0.17 1.76 ± 1* 2.00 ± 1.98*
Body weight (kg) 74.7 ± 11.9 76.1 ± 8.0 75.4 ± 12.5
No of years of follow‑up 12.3 ± 7.7 16.3 ± 3.4
No of years from biopsy to ESRD 5.8 ± 2.5
 Percentage with M‑score of 1 Not applicable 31.3% 44.4%
 Percentage with E‑score of 1 Not applicable 31.3% 33.3%
 Percentage with S‑score of 1 Not applicable 50% 77.8%
 Percentage with T‑score of 1 or 2 Not applicable 0% 44.4%*
Table 2 List of the 25 proteins with the highest fold-change between IgAN with versus without progression, only signifi-
cantly changed proteins included in list
UniProtKB accession N unique peptides Protein name Fold change p value
O00391 4 Sulfhydryl oxidase 1 3.33 0.004
P13671 16 Complement C6 2.95 0.0003
P10643 14 Complement C7 2.65 0.001
P08519 7 Apolipoprotein(a) 2.58 0.004
P11215 4 Integrin alpha‑M 2.56 0.03
P00736 2 Complement C1r subcomponent 2.53 0.001
P01876 21 Ig alpha‑1 chain C region 2.35 0.02
P01019 4 Angiotensinogen 2.26 0.03
P68032 2 Actin, alpha cardiac muscle 1 2.21 0.02
P0C0L5 5 Complement C4‑B 2.20 0.01
Q9GIY3 2 HLA class II histocompatibility antigen, DRB1‑14 beta chain 2.16 0.05
P22102 4 Trifunctional purine biosynthetic protein adenosine‑3 2.07 0.002
P04114 32 Apolipoprotein B‑100 2.01 0.04
P07358 14 Complement C8 beta chain 1.97 0.01
P07357 19 Complement C8 alpha chain 1.97 0.001
P01031 39 Complement C5 1.93 0.01
Q9HCU0 2 Endosialin 1.87 0.05
P04003 14 C4b‑binding protein alpha chain 1.86 0.01
P31947 2 14‑3‑3 protein sigma 1.84 0.03
P07225 3 Vitamin K‑dependent protein S 1.84 0.03
P36980 3 Complement factor H‑related protein 2 1.84 0.003
O15143 7 Actin‑related protein 2/3 complex subunit 1B 1.83 0.03
Q15063 10 Periostin 1.79 0.04
Q9BXR6 22 Complement factor H‑related protein 5 1.79 0.01
Q9BY44 2 Eukaryotic translation initiation factor 2A 1.76 0.03
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Complement proteins in progressive 
versus non‑progressive IgAN
In the comparison between progressive versus non-
progressive IgAN, 18 complement proteins were sig-
nificantly different, 17 proteins were more abundant 
and one (complement receptor 1, CR1) were less abun-
dant (Table  3). Complement components that had sig-
nificantly increased abundance were C1q, C1r, C1s, C3, 
C4-B, C5, C6, C7, C8 and C9. Complement regulators 
also had increased abundance, including clusterin, factor 
H, factor H-related proteins 2, 5 and C4b-binding protein 
alpha chain..
The proteins that were significantly changed in progres-
sive versus non-progressive IgAN patients were mapped 
to the complement pathway (Fig. 1). Further analyses of 
the complement factor subcomponents of C2, C4 and 
C5 were unfortunately not possible due to few specific 
peptides. For C3 we did however identify 105 peptides, 
of which 65 peptides could be used for analysis of sub-
components. Fold-change for specific C3 peptides were: 
C3 beta chain 1.30 (p =  0.002), C3c alpha1 chain 1.22 
(p = 0.3), C3c alpha-2 chain 1.30 (p = 0.002) and C3dg 
2.16 (p = 0.000005) (Additional file 1: Table S1).
Complement proteins in non‑progressive IgAN 
versus controls
In the comparison between patients with non-progres-
sive IgAN and controls, 19 proteins were significantly 
Table 3 Change in abundance for quantified complement and complement related proteins for progressive versus non-
progressive IgAN and for non-progressive IgAN versus control




Fold change p value Fold change p value
Complement system components
P02746 4 Complement C1q subcomponent subunit B 1.18 0.57 1.47 0.002
P02747 4 Complement C1q subcomponent subunit C 1.54 0.04 1.18 0.53
P00736 2 Complement C1r subcomponent 2.53 0.001 0.97 0.11
P09871 2 Complement C1s subcomponent 1.43 0.02 1.26 0.28
P00751 17 Complement factor B 1.06 0.68 1.01 0.74
P06681 2 Complement C2 1.36 0.13 1.07 0.57
P01024 105 Complement C3 1.46 0.01 1.93 0.0001
P0C0L4 44 Complement C4‑A 1.31 0.45 1.25 0.01
P0C0L5 5 Complement C4‑B 2.20 0.01 1.01 0.80
P01031 39 Complement C5 1.93 0.01 2.45 0.00002
P13671 16 Complement C6 2.95 0.0003 1.89 0.0005
P10643 14 Complement C7 2.65 0.001 3.76 0.00001
P07357 19 Complement C8 alpha chain 1.97 0.001 2.51 0.0003
P07358 14 Complement C8 beta chain 1.97 0.01 2.20 0.0003
P07360 10 Complement C8 gamma chain 1.72 0.0002 1.28 0.001
P02748 25 Complement C9 1.65 0.03 4.10 0.00004
Complement system regulators
P13987 2 CD59 glycoprotein 1.26 0.14 1.29 0.07
P10909 14 Clusterin 1.68 0.0004 1.39 0.01
P08603 38 Complement factor H 1.34 0.02 1.58 0.0003
Q03591 9 Complement factor H‑related protein 1 1.72 0.10 3.96 0.0002
P36980 3 Complement factor H‑related protein 2 1.84 0.003 2.79 0.002
Q02985 4 Complement factor H‑related protein 3 2.18 0.08 1.54 0.049
Q9BXR6 22 Complement factor H‑related protein 5 1.79 0.01 2.67 0.0002
P17927 13 Complement receptor type 1 0.63 0.04 0.62 0.001
Q2VPA4 4 Complement component receptor 1‑like protein 0.72 0.07 0.64 0.01
P04003 14 C4b‑binding protein alpha chain 1.86 0.01 0.99 0.87
P04004 18 Vitronectin 1.16 0.18 1.75 0.001
P05155 4 Plasma protease C1 inhibitor 1.51 0.26 1.04 0.65
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differently abundant, 17 were more abundant and two 
were less abundant (Table  3), a similar pattern to that 
observed for the comparison between progressive and 
non-progressive IgAN.
Immunohistochemistry
Representative pictures illustrating immunohistochem-
istry staining for the three groups are shown in Fig.  2. 
Scores for glomerular staining for C1q was similar 
between the groups (0.57 ± 0.78 in controls, 0.43 ± 0.64 
in non-progressive IgAN and 0.38 ± 0.52 in progressive 
IgAN). Scores for C3 staining were different between 
groups (0.14  ±  0.38, 0.71  ±  0.61 and 1.38  ±  0.91, 
respectively; p for trend 0.005, p =  0.055 for compari-
son progressive versus non-progressive IgAN). Scores 





















































Fig. 1 Illustration of the complement activation pathway with annotations for quantified glomerular proteins in progressive versus non‑progressive 
IgAN patients. C1INH, plasma protease C1 inhibitor; C4BP, C4b‑binding protein; CR1, Complement receptor type 1; FB, factor B; MASP, mannose‑
associated serine protease. All other abbreviations are names of the complement components or subcomponents
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between non-progressive and progressive IgAN patients 
(0.64 ± 1.02 vs 0.71 ± 1.11).
Prediction of progressive versus non‑progressive IgAN
As shown above, glomerular protein abundance of comple-
ment proteins were higher in patients with IgAN with pro-
gressive disease as compared to IgAN with non-progressive 
disease. We further analysed whether glomerular abun-
dance of these proteins could classify IgAN patients as pro-
gressive versus non-progressive. Unsupervised hierarchical 
clustering including only the significantly abundant com-
plement related proteins of Table 3 separated most patients 
with progressive and non-progressive disease (Fig. 3).
A complement score was calculated for each patients 
based on abundance of complement related proteins (for 
details, see “Methods” section). Patients with progressive 
IgAN had significantly higher scores than patients with 
non-progressive IgAN, and controls had lower scores 
than non-progressive IgAN. We further tested whether 
these scores could be used to classify patients with pro-
gressive versus non-progressive IgAN. In ROC analy-
ses, AUC values were 0.91 (p = 0.001) for a complement 
score using all significant proteins, 0. 91 (p = 0.001) for 
the complement score including complement com-
ponents C5, C6, C7, C8 and C9 and 0.90 (p  =  0.001) 
when only including protein abundance of complement 
Fig. 2 Representative immunohistochemistry staining images for complement factors C1q, C3 and membrane attack complex (C5b‑9) for a repre‑
sentative control, a representative patient with non‑progressive IgAN and a representative patient with progressive IgAN
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factor C7, the rate limiting factor of the terminal pathway 
(Fig. 4). In comparison, AUC value for the clinical vari-
ables systolic blood pressure was 0.580 (p = 0.5) and for 
the variable 1/eGFR it was 0.74 (p = 0.054). Other clini-
cal or morphological variables could neither be used to 
classify progressive from non-progressive IgAN.
Associations between complement proteins and clinical 
variables
For patients with IgAN, linear associations between the 
complement proteins and clinical variables were investi-
gated. These analyses showed that C1r, C1s, C5, C6, C8, 
C9 and clusterin had higher abundance with lower eGFR 
(Table  4). There were no significant associations with 
urinary protein, but there were increased abundances of 
the C1r, C1s, C4, C5, C8, C9, factor H, factor H-related 
protein 3 and C4b binding protein alpha with increasing 
systolic blood pressure.
Associations between complement proteins and MEST 
score
Distribution of MEST scores are shown in Table 1. Com-
plement levels were compared between IgAN patients 
with positive as compared to negative scores for the 4 dif-
ferent MEST characteristics (Table  5). Positive M score 
was associated with higher abundance of complement 
proteins C5, C6, C7, C8, and clusterin, and lower abun-
dance of complement receptor type 1. Positive E score 
was associated with higher abundance of C5, C7, C9 and 
complement factor H-related protein 5. Positive S score 
was associated with higher abundance of C1r and C1s. 
Positive T score was associated with higher abundance of 
C1q, C1r, C1s, C4, C5, C6, C7, C8 clusterin, complement 
factor H and C4b-binding protein, and lower abundance 
of complement receptor type 1.
Discussion
In the current study we have shown that patients with 
progressive IgAN had higher glomerular abundance 
of complement proteins as compared to patients with 
non-progressive IgAN. Interestingly, both ordinary 
complement components and most of the comple-
ment inhibitors showed higher abundance, indicating 
Fig. 3 Hierarchical clustering for proteins significantly different between progressive (IgA+) versus non‑progressive IgAN (IgA−)
Fig. 4 ROC curves for complement scores, systolic blood pressure 
and eGFR
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compensatory mechanisms taking place during activa-
tion. IgAN patients selected for the present study had 
medium risk of progression and prognosis could not be 
predicted based on accepted risk factors such as eGFR, 
proteinuria, blood pressure or the Oxford classification. 
Glomerular abundance of all significant complement 
proteins, in particular those of the terminal pathway, 
did however show predictive performance with area 
under the ROC curve of about 0.9. Similar findings for 
complement proteins were made when comparing non-
progressive IgAN patients to controls, indicating a dose–
response relationship.
In the present study we were able to quantify 28 comple-
ment proteins. We found increased abundance of proteins 
related to the classical and terminal pathway. Members 
of the terminal pathway (complement factors C5–C9) 
that constitute the MAC, showed the strongest increase 
in progressive versus non-progressive IgAN as well as in 
non-progressive IgAN versus controls. Previous studies 
have shown increased glomerular MAC deposition [19] 
and increased urinary MAC levels [20] in IgA nepropathy. 
The prognostic importance has however not been shown 
before. Local expression of terminal pathway components 
in renal cells has not been described [21] indicating that 
our finding are suggestive of complement activation and 
not just local synthesis. In Fig. 2 we show mesangial local-
ization of the membrane attack complex with an antibody 
against a neoepitope in C9 that only stain positive for the 
assembled complex, indicating activation of the complex 
and not just deposition of the native component.
In our study, components of the classical pathway C1q, 
C1r and C1s, were significantly increased in patients with 
progressive IgAN as compared with non progressive 
IgAN, suggesting the involvement of the classical path-
way in the progression of the diseases. In our study, we 
could not detect MASP (mannose binding lectin associ-
ated serine proteases), MBL (mannose binding lectin) or 
ficolins and we could thus not find evidence for activation 
of the lectin pathway. We thus suggest that the increased 
abundance of complement component C4 in progressive 
IgAN may argue for contribution of the classical pathway 
in IgAN patients with progressive disease.
Furthermore, complement C3 mesangial deposition 
was also significantly increased in progressive IgAN. The 
Table 4 Linear associations between complement related proteins significantly altered in Table 3 in the comparison pro-
gressive versus non-progressive IgAN and clinical variables at time of biopsy
Only IgAN patients
* Direction of association is shown, + means higher intensity with higher value for clinical marker and − means lower intensity with higher value for clinical marker
eGFR Urinary protein Systolic blood pres‑
sure
B* p value B* p value B* p value
Complement system components
Complement C1q subcomponent subunit C − 0.3 + 0.2 + 0.5
Complement C1r subcomponent − 0.003 + 0.5 + 0.02
Complement C1s subcomponent − 0.005 + 0.7 + 0.003
Complement C3 − 0.3 − 0.5 + 0.2
Complement C4‑B − 0.2 + 0.9 + 0.05
Complement C5 − 0.04 − 0.3 + 0.02
Complement C6 − 0.03 − 0.3 + 0.09
Complement C7 − 0.06 − 0.5 + 0.2
Complement C8 alpha chain − 0.03 − 0.4 + 0.05
Complement C8 beta chain − 0.02 − 0.2 + 0.004
Complement C8 gamma chain − 0.1 + 0.6 + 0.4
Complement C9 − 0.01 − 0.24 + 0.01
Complement system regulators
Clusterin − 0.02 − 0.3 + 0.1
Complement factor H − 0.1 − 0.5 + 0.02
Complement factor H‑related protein 1 − 0. 4 − 0.8 + 0.1
Complement factor H‑related protein 2 + 0.9 − 0.9 + 0.5
Complement factor H‑related protein 5 − 0.3 − 0.5 + 0.5
Complement receptor type 1 + 0.07 + 0.9 − 0.4
C4b‑binding protein alpha chain − 0.06 − 0.4 + <0.001
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alternative pathway is suggested to be activated in IgAN 
as complement C3 mesangial deposition is present in 
>90% of patients and Immunglobulin A has been shown 
to activate the alternative pathway  in vitro [7, 22]. As 
C3 is present both by activation of the classical and the 
lectin pathtay by the amplification loop, it is not possi-
ble to know with certainty whether or not the alternative 
pathway was activated primarily in IgGAN. Interestingly, 
analyses of the subcomponents of C3 showed stronger 
increase of C3dg than the other peptides in progressive 
IgAN. C3dg is an inactive product of degraded C3b and 
our findings thus indicate increased opsonization by 
C3b in patients with progressive IgAN. Similar findings 
of accumulation of C3dg was recently also shown for C3 
glomerulopathy [23]. Other regulators of the comple-
ment system, such as factor H, which is one of the most 
important regulators of C3 and the alternative pathway, 
were also mostly significantly increased in progres-
sive IgAN. These findings suggest that compensatory 
mechanisms are active in IgAN in order to control the 
increased complement activation. One inhibitor of the 
complement system, complement receptor 1 (CR1) that 
acts by inactivating C3b and is localized on the podo-
cytes [24] was however present in lower abundance in 
progressive IgAN. Previous studies have shown reduced 
CR1 in injured podocytes from patients with differ-
ent types of glomerulopathies [25] and one study also 
showed reduced CR1 expression in lupus nephritis [26]. 
The decrease in CR1 may contribute to a disturbed bal-
ance with increased activation and reduced inhibition, 
enhancing the detrimental effects of complement acti-
vation in IgAN. The exact mechanisms for complement 
activation and regulation in IgAN cannot howver be 
mapped by the present study, but the clear evidence of its 
prognostic role points to a need for further studies.
In the selection of IgAN patients for the present study, 
we aimed to include patients with medium risk of pro-
gression and a progressive versus non-progressive dis-
ease course. The rationale for the selection criteria based 
on eGFR and proteinuria was to select patients in whom 
prediction of prognosis was difficult based on traditional 
risk factors and indeed, prognosis could not be predicted 
based on classical risk factors. Initially, we planned to 
include only patients with proteinuria of 1–3.5  g/24  h, 
but due to a limited number of patients with these char-
acteristics, we chose to add 3 patients with proteinuria 
less than 1 g/24 h who progressed to ESRD and 1 patient 
with proteinuria above 3.5 g/24 h who did not progress 
to ESRD. In our opinion this approach yielded two 
groups with progressive versus non-progressive disease 
Table 5 Glomerular complement protein abundance in IgAN patients according to MEST score; only proteins significant 
in Table 3 are included
M1 versus M0 E1 versus E0 S1 versus S0 T1/2 versus T0
Fold change p value Fold change p value Fold change p value Fold change p value
Complement system components
Complement C1q subcomponent subunit C 0.9 0.88 1.1 0.57 1.1 0.71 2.7 0.02
Complement C1r subcomponent 0.8 0.81 1.5 0.37 1.6 0.03 2.7 0.02
Complement C1s subcomponent 0.9 0.76 1.7 0.05 1.5 0.04 2.0 0.01
Complement C3 1.5 0.05 1.5 0.06 0.9 0.86 1.5 0.15
Complement C4‑B 1.1 0.75 0.8 0.21 1.3 0.65 2.6 0.01
Complement C5 2.5 0.03 2.3 0.02 1.1 0.57 2.3 0.04
Complement component C6 2.1 0.04 1.7 0.07 0.9 0.69 2.7 0.02
Complement component C7 2.2 0.02 2.4 0.03 1.1 0.55 3.3 0.03
Complement component C8 alpha chain 2.3 0.02 2.2 0.05 1.0 0.64 2.4 0.04
Complement component C8 beta chain 2.0 0.06 2.0 0.05 0.9 0.98 1.8 0.07
Complement component C8 gamma chain 1.7 0.002 1.4 0.05 1.2 0.47 1.6 0.01
Complement component C9 2.3 0.06 2.2 0.04 0.9 0.67 1.9 0.07
Complement system regulators
Clusterin 1.8 0.003 1.4 0.14 1.2 0.28 1.9 0.01
Complement factor H 1.4 0.09 1.5 0.07 1.3 0.33 1.7 0.01
Complement factor H‑related protein 1 2.3 0.07 2.2 0.16 1.2 0.85 2.4 0.10
Complement factor H‑related protein 2 1.7 0.11 1.8 0.07 1.2 0.90 1.5 0.20
Complement factor H‑related protein 5 1.6 0.09 1.4 0.04 0.9 0.94 1.6 0.19
Complement receptor type 1 0.5 0.003 0.6 0.10 0.8 0.30 0.4 0.001
C4b‑binding protein alpha chain 0.9 0.67 1.2 0.60 1.2 0.16 2.6 0.001
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for whom prediction of prognosis was very difficult, in 
strong line with the rationale described above.
Complement score, either based on abundance of signifi-
cant complement proteins, and in particular components 
of the membrane attack complex, could however predict 
prognosis with area under ROC curve of about 0.9. Unsu-
pervised hierarchical clustering also showed the same, con-
firming and strengthening these findings. Two important 
reservations should however be made. First, the predictive 
capacity could not be reproduced with immunohistochem-
istry staining for C5b-9, and staining for C3 was only mod-
erately increased in patients with progressive IgAN, the 
direct clinical significance should therefore be interpreted 
with caution. Second, we investigated the predictive ability 
of the complement scores in the same cohort in which we 
demonstrated the importance and not in a separate cohort. 
Our results therefore need confirmation in a new cohort. A 
previous study also showed prognostic importance of C4d 
staining, this staining was not tested in our study [27].
The most important strengths of the present study 
are the relevant study population with IgAN in whom 
the prognosis was difficult to predict, microdissection 
and analysis of the relevant glomerular tissue, the large 
number of quantified proteins and the dose–response 
relationships that were seen for progressive IgAN versus 
non-progressive IgAN versus controls.
Conclusions
In conclusion, the present study has shown increased 
abundance of complement factors and inhibitors in pro-
gressive IgAN as compared to non-progressive IgAN. 
Increased abundance of proteins of the terminal comple-
ment pathway argue for complement-mediated damage 
in progressive IgAN. One inhibitor of the complement 
system, CR1, had lower abundance in progressive IgAN 
and may represent a mechanism that reduces comple-
ment inhibitory control in IgAN.
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